贝那普利对糖耐量减低患者的干预作用

目的 :观察贝那普利对糖耐量减低 (IGT)患者的干预作用。方法 :75g葡萄糖耐量试验 (OGTT)确诊IGT 70例 ,其中男 31例 ,女 39例 ,随机分成贝那普利组、对照组各 35例。对照组进行饮食、运动控制 ,贝那普利组除饮食、运动控制外 ,加贝那普利10mgqd ,观察 12周。结果 :治疗后两组空腹血糖(FBG)及舒张压均下降 ,但两组间差异无显著的统计学意义 (P >0 .0 5 ) ;对照组治疗后收缩压无下降 ,而贝那普利组有所下降 (P <0 .0 1) ;两组治疗后的餐后 2h血糖 (P2HBG)及糖化血红蛋白 (HbA1c)均下降 ,贝那普利组优于对照组 (P <0 .0 5 )。结论 :贝那普利可降低糖耐量减低患者P2HBG、HbA1c及收缩压水平 ,提示贝那普利可改善糖耐量减低患者代谢紊乱。

Intervention of bennazepril in the patients with impaired glucose tolerance

AIM: To explore the intervention of bennazepril in patients with impaired glucose tolerance (IGT). METHODS: Seventy patients with first diagnosed IGT were enrolled in this study. The control group involved 35 patients dealt with diet and exercise, and the trial group involved 35 patients dealt with diet, exercise and bennazepril. The changes of fasting blood glucose (FBG), 2-hour postprandial blood glucose (P2HBG), systolic blood pressure (SBP), diastolic blood pressure (DBP) and glycosylated hemoglobin (HbA 1c) values were assayed. RESULTS: After the treatment of 12 weeks, the decreased values of fasting blood glucose and diastolic blood pressure were not difference (P> 0.05), but in the trial group, decreased values of 2-hour postprandial blood glucose and glycosylated hemoglobin A 1c decreased (P< 0.05), and systolic blood pressure also decreased (P< 0.01). CONCLUSIONS: Bennazepril can decrease the 2-hour postprandial blood glucose, glycosylated hemoglobin A 1c and systolic blood pressure. It suggests that Bennazepril can improve the metabolic disorder in patients with IGT.